Table 6.
Multivariate Cox Regression for OS among patients of Breast Cancer Liver Metastases with or without HER2-targeted therapy in the FUSCC dataset
| Variable | Overall Survival With HER2-targeted therapy | Overall Survival Without HER2-targeted therapy | ||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Subtype | ||||
| HR+/HER2− | 1[Reference] | 1[Reference] | ||
| HR+/HER2+ | 0.74 (0.58–0.95) | 0.017* | 2.62 (1.88–3.66) | < 0.001* |
| HR−/HER2+ | 0.81 (0.63–1.05) | 0.110 | 3.43 (2.29–5.15) | < 0.001* |
| Triple-negative | 2.17 (1.78–2.63) | < 0.001* | 2.17 (1.78–2.63) | < 0.001* |
Adjust for other variables
+ denotes positive; − denotes negative; * denotes a statistically significant P-value; HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, CI Confidence interval